CDKN2B-AS1 and non-small cell lung carcinoma: We further validated the expression pattern of SOX2OT and ANRIL lncRNA and the efficiency of the 5‐molecule panel estimated during the training stage by employing another independent validation set (100 NSCLC patients and 100 controls).